keyword
Keywords Opioid induced respiratory dep...

Opioid induced respiratory depression

https://read.qxmd.com/read/38584476/opioid-induced-respiratory-depression-suspected-of-drug-interaction-in-a-prostate-cancer-patient-a-case-report
#1
JOURNAL ARTICLE
Hiroshi Hamada, Eisuke Suzuki, Mitsufumi Endo, Yukiko Mihara, Sayaka Iketani, Miki Ishida, Akime Miyasato, Kanako Miyazaki
BACKGROUND: Many of the drugs used for the treatment and alleviation of symptoms in cancer patients are known to inhibit or induce cytochrome P450 (CYP). Therefore, it is important to pay attention to the drug interactions of opioid analgesics that are metabolized by CYPs, because for example when using oxycodone metabolized by CYP3A4, it is possible that the effect will be attenuated or enhanced by the concomitant use of drugs that induce or inhibit CYP3A4. Aprepitant, an antiemetic drug used in many patients receiving anticancer drugs, is known as a moderate competitive inhibitor of CYP3A4...
March 2024: Annals of Palliative Medicine
https://read.qxmd.com/read/38570601/pbpk-pd-model-for-predicting-morphine-pharmacokinetics-cns-effects-and-naloxone-antagonism-in-humans
#2
JOURNAL ARTICLE
Rui-Jing Mu, Tian-Lei Liu, Xiao-Dong Liu, Li Liu
Morphine and morphine-6-glucuronide (M6G) produce central nervous system (CNS) effects by activating mu-opioid receptors, while naloxone is used mainly for the reversal of opioid overdose, specifically for the fatal complication of respiratory depression, but also for alleviating opioid-induced side effects. In this study we developed a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model to simultaneously predict pharmacokinetics and CNS effects (miosis, respiratory depression and analgesia) of morphine as well as antagonistic effects of naloxone against morphine...
April 3, 2024: Acta Pharmacologica Sinica
https://read.qxmd.com/read/38570042/development-of-fentanyl-specific-monoclonal-antibody-mab-to-antagonize-the-pharmacological-effects-of-fentanyl
#3
JOURNAL ARTICLE
Xiao-Yi Chen, Li Wang, Xiao Ma, Fan Yang, Xiao Wang, Peng Xu, Li-Li Xu, Bin Di
Fentanyl, a critical component of illicit drugs, poses a severe threat to public health, exacerbating the drug problem due to its potential fatality. Herein, we present two novel haptens designed with different attachment sites conjugated to keyhole limpet hemocyanin (KLH), aiming to develop an efficacious vaccine against fentanyl. KLH-Fent-1 demonstrated superior performance over KLH-Fent-2 in antibody titer, blood-brain distribution, and antinociceptive tests. Consequently, we immunized mice with KLH-Fent-1 to generate fentanyl-specific monoclonal antibodies (mAbs) using the hybridoma technique to compensate for the defects of active immunization in the treatment of opioid overdose and addiction...
April 1, 2024: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/38566055/prescription-opioid-dispensing-patterns-among-patients-with-schizophrenia-or-bipolar-disorder
#4
JOURNAL ARTICLE
Brittany D Roy, Jianheng Li, Cathy Lally, Sarah C Akerman, Maria A Sullivan, James Fratantonio, William Dana Flanders, Madé Wenten
BACKGROUND: Patients with schizophrenia (SZ) or bipolar disorder (BD) may have increased risk of complications from prescribed opioids, including opioid-induced respiratory depression. We compared prescription opioid pain medication dispensing for patients with SZ or BD versus controls over 5 years to assess dispensing trends. METHODS: This retrospective, observational study analysed US claims data from the IBM® MarketScan® Commercial and Multi-State Medicaid databases for individuals aged 18-64 years with prevalent SZ or BD for years 2015-2019 compared with age- and sex-matched controls...
April 2, 2024: BMC Psychiatry
https://read.qxmd.com/read/38550534/evaluating-the-rate-of-reversal-of-fentanyl-induced-respiratory-depression-using-a-novel-long-acting-naloxone-nanoparticle-cnlx-np
#5
JOURNAL ARTICLE
Saadyah E Averick, Andrew J Kassick, Daihyun Song, Borui Zhang, Jennifer Vigliaturo, Diego Luengas, Pedro Silva-Ortiz, Marco Pravetoni, Michael D Raleigh
INTRODUCTION: Fentanyl and fentanyl analogs (F/FA) have become increasingly common adulterants in counterfeit prescription pills and illicit street drug mixtures due to their ease of synthesis and exceedingly high potency. The ongoing epidemic of fatal overdoses fueled by F/FA continues to highlight the need for longer-acting therapies than naloxone (NLX), the current gold-standard for reversing opioid overdoses, which shows limited efficacy to prevent renarcotization associated with F/FA toxicity...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38523636/case-report-successful-induction-of-buprenorphine-in-medically-complex-patients-concurrently-on-opioids-a-case-series-at-a-tertiary-care-center
#6
Thomas Shelton, Sharanya Nama, Orman Hall, Margaret Williams
Effective pain management is essential for optimal surgical outcomes; however, it can be challenging in patients with a history of opioid use disorder (OUD). Buprenorphine, a partial opioid agonist, is a valuable treatment option for patients with OUD. Initiating buprenorphine treatment in patients concurrently taking opioids can be complex due to potential adverse outcomes like precipitated withdrawal. Evolving guidelines suggest there are benefits to continuing buprenorphine for surgical patients throughout the perioperative period, however situations do arise when buprenorphine has been discontinued...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38504419/explaining-the-high-mortality-among-opioid-cocaine-co-users-compared-to-opioid-only-users-a-systematic-review
#7
REVIEW
Jan van Amsterdam, Wim van den Brink
RATIONALE: The opioid crisis in North America has recently seen a fourth wave, which is dominated by drug-related deaths due to the combined use of illicitly manufactured fentanyl [IMF] and stimulants such as cocaine and methamphetamine. OBJECTIVES: A systematic review addressing the question why drug users combine opioids and stimulants and why the combination results in such a high overdose mortality: from specific and dangerous pharmacokinetic or pharmacodynamic interactions or from accidental poisoning? RESULTS: Motives for the combined use include a more intensive high or rush when used at the same time, and some users have the unfounded and dangerous belief that co-use of stimulants will counteract opioid-induced respiratory depression...
March 19, 2024: Journal of Addictive Diseases
https://read.qxmd.com/read/38497192/gastrointestinal-adverse-effects-associated-with-the-use-of-intravenous-oliceridine-compared-with-intravenous-hydromorphone-or-fentanyl-in-acute-pain-management-utilizing-adjusted-indirect-treatment-comparison-methods
#8
JOURNAL ARTICLE
Joseph Biskupiak, Gary Oderda, Diana Brixner, Todd L Wandstrat
Background: In the absence of head-to-head comparative data from randomized controlled trials, indirect treatment comparisons (ITCs) may be used to compare the relative effects of treatments versus a common comparator (either placebo or active treatment). For acute pain management, the effects of oliceridine have been compared in clinical trials to morphine but not to fentanyl or hydromorphone. Aim: To assess the comparative safety (specifically differences in the incidence of nausea, vomiting and opioid-induced respiratory depression [OIRD]) between oliceridine and relevant comparators (fentanyl and hydromorphone) through ITC analysis...
March 18, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38481848/fact-vs-fiction-naloxone-in-the-treatment-of-opioid-induced-respiratory-depression-in-the-current-era-of-synthetic-opioids
#9
REVIEW
Albert Dahan, Thomas S Franko, James W Carroll, David S Craig, Callie Crow, Jeffrey L Galinkin, Justin C Garrity, Joanne Peterson, David B Rausch
Opioid-induced respiratory depression (OIRD) deaths are ~80,000 a year in the US and are a major public health issue. Approximately 90% of fatal opioid-related deaths are due to synthetic opioids such as fentanyl, most of which is illicitly manufactured and distributed either on its own or as an adulterant to other drugs of abuse such as cocaine or methamphetamine. Other potent opioids such as nitazenes are also increasingly present in the illicit drug supply, and xylazine, a veterinary tranquilizer, is a prevalent additive to opioids and other drugs of abuse...
2024: Frontiers in Public Health
https://read.qxmd.com/read/38476879/multimodal-acute-pain-management-in-the-parturient-with-opioid-use-disorder-a-review
#10
REVIEW
Victor Koltenyuk, Ismat Mrad, Ian Choe, Mohamad Ibrahim Ayoub, Sangeeta Kumaraswami, Jeff L Xu
The opioid epidemic in the United States has led to an increasing number of pregnant patients with opioid use disorder (OUD) presenting to obstetric units. Caring for this complex patient population requires an interdisciplinary approach involving obstetricians, anesthesiologists, addiction medicine physicians, psychiatrists, and social workers. The management of acute pain in the parturient with OUD can be challenging due to several factors, including respiratory depression, opioid tolerance, and opioid-induced hyperalgesia...
2024: Journal of Pain Research
https://read.qxmd.com/read/38444495/use-of-noisy-labels-as-weak-learners-to-identify-incompletely-ascertainable-outcomes-a-feasibility-study-with-opioid-induced-respiratory-depression
#11
JOURNAL ARTICLE
Alvin D Jeffery, Daniel Fabbri, Ruth M Reeves, Michael E Matheny
OBJECTIVE: Assigning outcome labels to large observational data sets in a timely and accurate manner, particularly when outcomes are rare or not directly ascertainable, remains a significant challenge within biomedical informatics. We examined whether noisy labels generated from subject matter experts' heuristics using heterogenous data types within a data programming paradigm could provide outcomes labels to a large, observational data set. We chose the clinical condition of opioid-induced respiratory depression for our use case because it is rare, has no administrative codes to easily identify the condition, and typically requires at least some unstructured text to ascertain its presence...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38436495/reversal-of-opioid-induced-respiratory-depression-in-healthy-volunteers-comparison-of-intranasal-nalmefene-and-intranasal-naloxone
#12
JOURNAL ARTICLE
Mark Ellison, Emily Hutton, Lynn Webster, Phil Skolnick
An open-label, randomized, crossover study in healthy volunteers compared the reversal of remifentanil-induced respiratory depression by intranasal (IN) naloxone hydrochloride (4 mg) to IN nalmefene (2.7 mg) (NCT04828005). Subjects were administered a hypercapnic gas mixture which produces an elevation in minute ventilation (MV), a result of the ventilatory response to hypercapnia. Subjects breathed a hypercapnic gas mixture through a tight-fitting mask for an initial period of 46 min prior to a series of mask "holidays" introduced to reduce subject discomfort and encourage study completion...
March 4, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38409115/-comparison-of-the-%C3%A2%C2%B5-opioid-receptor-antagonists-methocinnamox-mcam-and-naloxone-to-reverse-and-prevent-the-ventilatory-depressant-effects-of-fentanyl-carfentanil-3-methylfentanyl-and-heroin-in-male-rats
#13
JOURNAL ARTICLE
Takato Hiranita, Nicholas P Ho, Charles P France
The number of opioid overdose deaths has increased significantly over the past decade. The life-threatening effect of opioids is hypoventilation that can be reversed by the µ-opioid receptor (MOR) antagonist naloxone; however, because of the very short duration of action of naloxone, re-emergence of MOR agonist-induced hypoventilation can occur, requiring additional doses of naloxone. The MOR antagonist methocinnamox (MCAM) antagonizes hypoventilation by the non-morphinan fentanyl and the morphinan heroin in laboratory animals with an unusually long duration of action...
February 26, 2024: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/38409113/-ncp-a-dual-kappa-and-mu-opioid-receptor-agonist-is-a-potent-analgesic-against-inflammatory-pain-without-reinforcing-or-aversive-properties
#14
JOURNAL ARTICLE
Peng Huang, Conrad K Ho, Danni Cao, Saadet Inan, Scott M Rawls, Mengchu Li, Boshi Huang, Piyusha P Pagare, E Andrew Townsend, Justin L Poklis, Matthew S Halquist, Matthew Banks, Yan Zhang, Lee-Yuan Liu-Chen
While agonists of mu (MOR) and kappa (KOR) opioid receptors have analgesic effects, they produce euphoria and dysphoria, respectively. Other side effects include respiratory depression and addiction for MOR agonists and sedation for KOR agonists. We reported that 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-{[4'-(2'-cyanopyridyl)]carboxamido}cmorphinan (NCP) displayed potent KOR full agonist and MOR partial agonist activities (58%) with 6.5x KOR-over-MOR selectivity in vitro Herein, we characterized pharmacological effects of NCP in rodents...
February 26, 2024: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/38397910/tetrahydrocannabinol-and-cannabidiol-for-pain-treatment-an-update-on-the-evidence
#15
REVIEW
Kawthar Safi, Jan Sobieraj, Michał Błaszkiewicz, Joanna Żyła, Bartłomiej Salata, Tomasz Dzierżanowski
In light of the current International Association for the Study of Pain (IASP) clinical practice guidelines (CPGs) and the European Society for Medical Oncology (ESMO) guidelines, the topic of cannabinoids in relation to pain remains controversial, with insufficient research presently available. Cannabinoids are an attractive pain management option due to their synergistic effects when administered with opioids, thereby also limiting the extent of respiratory depression. On their own, however, cannabinoids have been shown to have the potential to relieve specific subtypes of chronic pain in adults, although controversies remain...
January 29, 2024: Biomedicines
https://read.qxmd.com/read/38385184/serotonin-therapies-for-opioid-induced-disordered-swallow-and-respiratory-depression
#16
JOURNAL ARTICLE
Michael Frazure, In Morimoto, Nathan Fielder, Nicholas Mellen, Kimberly Iceman, Teresa Pitts
Opioids are well-known to cause respiratory depression, but despite clinical evidence of dysphagia, effects of opioids on swallow excitability and motor pattern are unknown. We tested the effects of the clinically-relevant opioid buprenorphine on pharyngeal swallow and respiratory drive in male and female rats. We also evaluated the utility of 5-HT1A agonists (8-OH-DPAT and buspirone) to improve swallowing and breathing following buprenorphine administration. Experiments were performed on 44 freely breathing Sprague Dawley rats anesthetized with sodium pentobarbital...
February 22, 2024: Journal of Applied Physiology
https://read.qxmd.com/read/38375496/opioid-induced-respiratory-depression
#17
REVIEW
S C Jansen, A Dahan
No abstract text is available yet for this article.
March 2024: BJA Education
https://read.qxmd.com/read/38373600/enantiomeric-contributions-to-methamphetamine-s-bidirectional-effects-on-basal-and-fentanyl-depressed-respiration-in-mice
#18
JOURNAL ARTICLE
Harrison J Elder, D Matthew Walentiny, Patrick M Beardsley
RATIONALE: Fentanyl remains the primary cause of fatal overdoses, and its co-use with methamphetamine (METH) is a growing concern. We previously demonstrated that racemic METH can either enhance or mitigate opioid-induced respiratory depression (OIRD) dependent upon whether a low or high dose is administered. The optical isomers of METH, dextromethamphetamine (d-METH) and levomethamphetamine (l-METH), differ substantially in their selectivity and potency to activate various monoamine (MA) receptors, and these pharmacological differences may underlie the bidirectional effects of the racemate...
February 17, 2024: Pharmacology, Biochemistry, and Behavior
https://read.qxmd.com/read/38352435/use-of-noisy-labels-as-weak-learners-to-identify-incompletely-ascertainable-outcomes-a-feasibility-study-with-opioid-induced-respiratory-depression
#19
Alvin D Jeffery, Daniel Fabbri, Ruth M Reeves, Michael E Matheny
OBJECTIVE: Assigning outcome labels to large observational data sets in a timely and accurate manner, particularly when outcomes are rare or not directly ascertainable, remains a significant challenge within biomedical informatics. We examined whether noisy labels generated from subject matter experts' heuristics using heterogenous data types within a data programming paradigm could provide outcomes labels to a large, observational data set. We chose the clinical condition of opioid-induced respiratory depression for our use case because it is rare, has no administrative codes to easily identify the condition, and typically requires at least some unstructured text to ascertain its presence...
January 30, 2024: medRxiv
https://read.qxmd.com/read/38334297/medication-induced-central-sleep-apnea-a-unifying-concept
#20
JOURNAL ARTICLE
Shahrokh Javaheri, W J Randerath, M Safwan Badr, Sogol Javaheri
Medication-induced central sleep apnea (CSA) is one of the 8 categories of causes of CSA but in the absence of awareness and careful history may be misclassified as primary CSA. While opioids are a well-known cause of respiratory depression and CSA, non-opioids medications including sodium oxybate, baclofen, valproic acid, gabapentin and ticagrelor are less well-recognized. Opioids-induced respiratory depression and CSA are mediated primarily by µ-opioid receptors, which are abundant in the pontomedullary centers involved in breathing...
February 9, 2024: Sleep
keyword
keyword
168560
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.